Real-World Outcomes of CDK4/6 Inhibitors Treatment in Metastatic Breast Cancer in Romania

Real-World Outcomes of CDK4/6 Inhibitors Treatment in Metastatic Breast Cancer in Romania

The introduction in clinical practice of selective cyclin-dependent kinase (CDK) 4/6 inhibitors improves the outcome of patients with hormone receptor (HR)-positive human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer (mBC). In Romania, the three available CDK 4/6 inhibi...

Full description

Bibliographic Details
Main Authors:	Andreea-Iuliana Miron, Alexandra-Valentina Anghel, Andrei-Alexandru Barnonschi, Ruxandra Mitre, Horia-Dan Liscu, Estera Găinariu, Raluca Pătru, Simona Coniac
Format:	Article
Language:	English
Published:	MDPI AG 2023-06-01
Series:	Diagnostics
Subjects:	CDK 4/6 inhibitors metastatic breast cancer HR+ progression-free survival real-world data
Online Access:	https://www.mdpi.com/2075-4418/13/11/1938

Similar Items

The Conditioning of Adjuvant Chemotherapy for Stage II and III Rectal Cancer Determined by Postoperative Pathological Characteristics in Romania
by: Horia-Dan Liscu, et al.
Published: (2023-06-01)

Immune effects of CDK4/6 inhibitors in patients with HR+/HER2− metastatic breast cancer: Relief from immunosuppression is associated with clinical response
by: Fabio Scirocchi, et al.
Published: (2022-05-01)

Association of ADME gene polymorphisms on toxicity to CDK4/6 inhibitors in patients with HR+ HER2- metastatic breast cancer
by: Elena Peruzzi, et al.
Published: (2023-11-01)

Clinical and Pharmacologic Differences of CDK4/6 Inhibitors in Breast Cancer
by: Mridula A. George, et al.
Published: (2021-07-01)

Challenges and Limitations of Endocrine Toxicity Evaluation in Non-Small Cell Lung Cancer Patients Treated with Immunotherapy—Retrospective Study from a Tertiary-Level Hospital in Romania
by: Simona Coniac, et al.
Published: (2023-05-01)

Assessing the Impact of Organ Failure and Metastases on Quality of Life in Breast Cancer Patients: A Prospective Study Based on Utilizing EORTC QLQ-C30 and EORTC QLQ-BR45 Questionnaires in Romania
by: Andreea-Iuliana Ionescu (Miron), et al.
Published: (2024-02-01)

Indirect Treatment Comparison of First-Line CDK4/6-Inhibitors in Post-Menopausal Patients with HR+/HER2− Metastatic Breast Cancer
by: Joseph J. Zhao, et al.
Published: (2023-09-01)

CDK4/6 Inhibitors in the First-Line Treatment of Postmenopausal Women with HR+/HER2− Advanced or Metastatic Breast Cancer: An Updated Network Meta-Analysis and Cost-Effectiveness Analysis
by: Ni Zeng, et al.
Published: (2023-06-01)

Genomic Markers of CDK 4/6 Inhibitor Resistance in Hormone Receptor Positive Metastatic Breast Cancer
by: Jin Sun Lee, et al.
Published: (2022-06-01)

Controversial topics in metastatic HR+/HER2- breast cancer: Guiding treatment by a modified Delphi approach
by: Alessandra Fabi, et al.
Published: (2022-09-01)

Targeted Therapy in HR+ HER2− Metastatic Breast Cancer: Current Clinical Trials and Their Implications for CDK4/6 Inhibitor Therapy and beyond Treatment Options
by: Constanze Elfgen, et al.
Published: (2021-11-01)

Dual Targeting of CDK4/6 and cMET in Metastatic Uveal Melanoma
by: Masahiro Ohara, et al.
Published: (2021-03-01)

Analysis of the efficacy and safety of eribulin therapy in patients with HR+/HER2- metastatic breast cancer pretreated with CDK4/6 inhibitors in real Russian practice
by: Irina V. Kolyadina, et al.
Published: (2021-05-01)

Mechanisms of Resistance to CDK4/6 Inhibitors and Predictive Biomarkers of Response in HR+/HER2-Metastatic Breast Cancer—A Review of the Literature
by: Ioana-Miruna Stanciu, et al.
Published: (2023-03-01)

CDK4/6 Inhibitors in Hormone Receptor-Positive Metastatic Breast Cancer: Current Practice and Knowledge
by: Debora de Melo Gagliato, et al.
Published: (2020-09-01)

How to Treat HR+/HER2- Metastatic Breast Cancer Patients after CDK4/6 Inhibitors: An Unfinished Story
by: Viola Cogliati, et al.
Published: (2022-03-01)

TWIST1 Upregulation Is a Potential Target for Reversing Resistance to the CDK4/6 Inhibitor in Metastatic Luminal Breast Cancer Cells
by: Nicoletta Cordani, et al.
Published: (2023-11-01)

A Protracted Course of COVID19 Infection in a Metastatic Breast Cancer Patient During CDK4/6 Inhibitor Therapy
by: Albert Grinshpun, et al.
Published: (2020-06-01)

Place of CDK 4/6 and PARP inhibitors in the modern treatment approach of HER2-negative breast cancer
by: Board Editorial
Published: (2021-11-01)

Abemaciclib in Combination With Endocrine Therapy for Patients With Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: A Phase 1b Study
by: Sara M. Tolaney, et al.
Published: (2022-02-01)

CDK4/6 inhibitors: A potential therapeutic approach for triple negative breast cancer
by: Lubaid Saleh, et al.
Published: (2021-12-01)

Targeting PEG10 as a novel therapeutic approach to overcome CDK4/6 inhibitor resistance in breast cancer
by: Nar Bahadur Katuwal, et al.
Published: (2023-11-01)

Does the Rechallenge with Another CDK 4/6 Inhibitor in Breast Cancer Work? A Case Report and Literature Review
by: Ioana-Miruna Stanciu, et al.
Published: (2023-04-01)

Prediction of Subclinical and Clinical Multiple Organ Failure Dysfunction in Breast Cancer Patients—A Review Using AI Tools
by: Andreea-Iuliana Ionescu (Miron), et al.
Published: (2024-01-01)

Correlations between Demographic, Clinical, and Paraclinical Variables and Outcomes in Patients with KRAS-Mutant or KRAS Wild-Type Metastatic Colorectal Cancer—A Retrospective Study from a Tertiary-Level Center in Romania
by: Edvina Elena Pîrvu, et al.
Published: (2023-09-01)

Role of pre-metastatic niche in organ specificity of breast cancer metastasis. Influence on metastatic potential as a basis for CDK4/6-inhibition efficacy in early therapy of disseminated hormone-receptor-positive disease
by: A. I. Stukan, et al.
Published: (2021-12-01)

CDK4/6 Inhibitors Overcome Endocrine ESR1 Mutation-Related Resistance in Metastatic Breast Cancer Patients
by: Stefania Crucitta, et al.
Published: (2023-02-01)

Relationship between Medication-Related Osteonecrosis of the Jaw and CDK4/6 Inhibitors in Breast Cancer
by: Loreto Domínguez Senín, et al.
Published: (2024-01-01)

Assessment of Resistance Mechanisms and Clinical Implications in Patients with KRAS Mutated-Metastatic Breast Cancer and Resistance to CDK4/6 Inhibitors
by: Lucrezia Raimondi, et al.
Published: (2021-04-01)

Progression-Free Survival and Overall Survival of CDK 4/6 Inhibitors Plus Endocrine Therapy in Metastatic Breast Cancer: A Systematic Review and Meta-Analysis
by: Michela Piezzo, et al.
Published: (2020-09-01)

Clinical outcomes of tucidinostat-based therapy after prior CDK4/6 inhibitor progression in hormone receptor-positive heavily pretreated metastatic breast cancer
by: Jinmei Zhou, et al.
Published: (2022-12-01)

CDK4/6 Inhibitors in Melanoma: A Comprehensive Review
by: Mattia Garutti, et al.
Published: (2021-05-01)

The role of CDK4/6 inhibitors in older and younger patients with breast cancer: A systematic review and meta-analysis
by: Fausto Petrelli, et al.
Published: (2023-10-01)

Molecular features evaluation of metastatic foci as the basis for metastatic breast cancer treatment personalization. Is there a place of CDK4/6-inhibitors in late-line therapy after chemotherapeutic regimens?
by: A. I. Stukan, et al.
Published: (2021-12-01)

The PI3K/AKT/mTOR and CDK4/6 Pathways in Endocrine Resistant HR+/HER2− Metastatic Breast Cancer: Biological Mechanisms and New Treatments
by: Daniele Presti, et al.
Published: (2019-08-01)

Recent advances of cyclin-dependent kinases as potential therapeutic targets in HR+/HER2− metastatic breast cancer: a focus on ribociclib
by: Edessa D, et al.
Published: (2017-12-01)

The Role of CDK4 in the Pathogenesis of Pancreatic Cancer
by: Emily Jiggens, et al.
Published: (2021-10-01)

Risk Factors for Palbociclib-Induced Early Developing Neutropenia in Patients with Hormone Receptor-Positive Metastatic Breast Cancer
by: Yeonhong Lee, et al.
Published: (2023-05-01)

CDK5: an oncogene or an anti-oncogene: location location location
by: Kumar Nikhil, et al.
Published: (2023-11-01)

Case report: 18F-FES PET/CT predicted treatment responses of second-line and third-line CDK4/6 inhibitors after disease progression on first-line CDK4/6 inhibitor in a HR+/HER2- metastatic breast cancer patient
by: Bo Pan, et al.
Published: (2022-12-01)